CNS Pharmaceuticals(CNSP)

Search documents
CNS Pharmaceuticals(CNSP) - 2022 Q1 - Quarterly Report
2022-05-12 16:00
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Name of registrant as specified in its charter) Nevada 82-2318545 (State or ...
CNS Pharmaceuticals(CNSP) - 2021 Q4 - Annual Report
2022-03-02 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-39126 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (St ...
CNS Pharmaceuticals (CNSP) Investor Presentation - Slideshow
2022-01-26 18:49
| --- | --- | --- | --- | |--------------|--------------|-------|------------------------------------------------------------------------------------| | | | | | | | | | | | | | | | | | | | | | NASDAQ: CNSP | | | | | | January 2022 | | www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 | 2 Forward-Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than st ...
CNS Pharmaceuticals(CNSP) - 2021 Q3 - Quarterly Report
2021-11-11 16:00
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Name of registrant as specified in its charter) Nevada 82-2318545 (Stat ...
CNS Pharmaceuticals(CNSP) - 2021 Q2 - Quarterly Report
2021-08-12 16:00
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Name of registrant as specified in its charter) Nevada 82-2318545 (State or ...
CNS Pharmaceuticals (CNSP) Investor Presentation - Slideshow
2021-05-20 19:16
| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | NASDAQ: CNSP | | | | MAY 2021 | | www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 | 2 Forward-Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial positi ...
CNS Pharmaceuticals(CNSP) - 2021 Q1 - Quarterly Report
2021-05-12 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) | - ...
CNS Pharmaceutical (CNSP) Investor Presentation - Slideshow
2021-03-12 19:39
| --- | --- | --- | --- | |---------------|-------|-------|------------------------------------------------------------------------------------| | | | | | | | | | | | | | | | | | | | | | Nasdaq: CNSP | | | | | FEBRUARY 2021 | | | www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 | 2 Disclaimer. This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than statements of historic ...
CNS Pharmaceuticals(CNSP) - 2020 Q4 - Annual Report
2021-02-11 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-39126 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (St ...
CNS Pharmaceuticals(CNSP) - 2020 Q3 - Quarterly Report
2020-11-12 21:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) ...